BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24067138)

  • 21. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
    Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
    Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
    Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
    Bringhen S; Offidani M; Palmieri S; Pisani F; Rizzi R; Spada S; Evangelista A; Di Renzo N; Musto P; Marcatti M; Vallone R; Storti S; Bernardini A; Centurioni R; Aitini E; Palmas A; Annibali O; Angelucci E; Ferrando P; Baraldi A; Rocco S; Andriani A; Siniscalchi A; De Stefano V; Meneghini V; Palumbo A; Grammatico S; Boccadoro M; Larocca A
    Crit Rev Oncol Hematol; 2018 Oct; 130():27-35. PubMed ID: 30196909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of novel drugs in multiple myeloma.
    Dimopoulos MA; Kastritis E
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii121-7. PubMed ID: 18790953
    [No Abstract]   [Full Text] [Related]  

  • 29. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
    An N; Li X; Shen M; Chen SL; Huang ZX
    Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
    [No Abstract]   [Full Text] [Related]  

  • 30. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
    J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on drug combinations for treatment of myeloma.
    Srikanth M; Davies FE; Morgan GJ
    Expert Opin Investig Drugs; 2008 Jan; 17(1):1-12. PubMed ID: 18095914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
    Wang X; Li Y; Yan X
    Biomed Res Int; 2016; 2016():6848902. PubMed ID: 26949704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
    Baz R; Miladinovic B; Patel A; Ho VQ; Shain KH; Alsina M; Nishihori T; Ochoa-Bayona JL; Sullivan DM; Dalton WS; Djulbegovic B
    Leuk Res; 2013 Sep; 37(9):1077-82. PubMed ID: 23809054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
    Fonseca R; Rajkumar SV
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):315-7. PubMed ID: 18854289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
    Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
    Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimising bortezomib in newly diagnosed multiple myeloma.
    Rajkumar SV
    Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.